Signature Dx to Use Affymetrix Chips for Cancer Test Development

Signature Dx will use Affy's microarray technology in two tests it is developing for colorectal cancer.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories